Navigation Links
JNCI April 28 tip sheet
Date:4/28/2009

Designing a Randomized Controlled Trial for Physical Activity, Weight Control, and Breast Cancer Risk

Researchers describe the rationale and a possible design for randomized controlled trials that test the impact of physical activity and weight control on breast cancer risk.

There are substantial observational data suggesting that regular physical activity and maintaining a healthy weight are associated with a reduction in breast cancer risk: however, it is unclear whether the apparent association is due to unknown confounding factors. An important way to determine if the lifestyle choices have a causal relationship with breast cancer risk is to test the hypothesis in the setting of a randomized controlled trial.

In the current commentary, Rachel Ballard-Barbash, M.D., of the National Cancer Institute in Bethesda, Md., and colleagues present designs for two trials, one in women who are at high risk of disease and one in breast cancer survivors. The interventions in the two trials could be the same; the goal for the weight control intervention would be a 10% weight loss for women with a body mass index above 25 kg/m2 at enrollment and avoidance of weight gain for those below 25 kg/m2. The goal for the physical activity intervention would be to achieve and maintain 150-220 minutes of physical activity per week.

"In conclusion, given the magnitude of the public health problem and the amount of accumulated evidence in support for this next level of scientific evidence, it is now appropriate to explore in detail the feasibility and timing of a large randomized trial to assess the effects of physical activity and weight control on breast cancer risk and/or prognosisand the trade-offs in moving toward the prevention vs the survival trial," the authors write.

Contact: NCI press office, ncipressofficers@mail.nih.gov, 301-496-6641


Clusterin Acts as a Tumor Suppressor Gene in Mouse Models of Neuroblastoma

Reduced expression of clusterin in a mouse model of neuroblastoma led to an increased number of tumors compared with control animals.

The role of clusterin in cancer has been unclear. Clusterin may affect processes related to cancer, including programmed cell death, motility, and inflammation.

In the current study, Arturo Sala, Ph.D., of the University College London Institute of Child Health, and colleagues used molecular techniques to increase or decrease expression of clusterin, MYCN, and a group of microRNAs named miR-17-19. MYCN and miR-17-19 microRNAs may regulate clusterin. The researchers assessed the impact of these changes in neuroblastoma cell lines and in animal models of neuroblastoma.

Increased expression of MYCN and miR-17-19 appeared to decrease the expression of clusterin, which was associated with increased tumor growth and metastasis. Increased clusterin expression was associated with reduced tumor growth and metastasis.

"We have provided, to our knowledge, the first evidence to show that clusterin is a tumor suppressor gene that is negatively regulated by the proto-oncogene MYCN," the authors write. "Mice with a disrupted clusterin gene developed more neuroblastomas than mice with a normal clusterin gene."

Contact:: Stephen Cox, Coxs@gosh.nhs.uk, +44(0) 20 7239 3125


Gene Expression Ratio Test Predicts Outcome in Mesothelioma Patients Treated with Surgery

A four-gene expression ratio test prospectively distinguished mesothelioma patients who had a statistically significant longer overall survival from those who had shorter survival in a single-institution study.

There are few effective treatment options available for patients with malignant pleural mesothelioma other than surgery. However, not all patients appear to derive benefit from surgery. Raphael Bueno, M.D., of the Brigham and Women's Hospital in Boston and colleagues showed in retrospective studies that measuring expression ratios of four genes could distinguish between those who have a good prognosis after surgery and those who have a poor prognosis.

In the current study, Bueno and colleagues tested the four-gene expression ratio test in 120 patients with mesothelioma who were treated at Brigham and Women's Hospital and participated in a prospective clinical trial. To evaluate the robustness and reproducibility of the test, the researchers evaluated the test on multiple tumor samples from each patient and used two different microarray platforms and two different biopsy techniques.

The test was able to predict overall survival after adjusting for other clinical factors. The test results were consistent for individual patients regardless of the techniques used for the test. When the researchers combined the gene ratio test results with known prognostic factors, they were able to separate patients into high-risk and low-risk groups. The median survival for patients in the high-risk group was 6.9 months compared with 31.9 months in the low-risk group.

"Patients whose gene ratio test results predict a good prognosis after surgery may more confidently select the treatment option that includes surgery," the authors write.

Contact: Raphael Bueno, M.D., rbueno@partners.org, 617 732 8148


Adult Survivors of Childhood Cancer Do Not Opt for Abortions More Frequently Than Their Healthy Sisters

Adult female survivors of childhood cancer do not opt for abortions more frequently than their sisters, according to data from a large Danish cohort study.

Previous studies suggested that women who had a childhood cancer may be concerned about the risks of having children and may choose to terminate a pregnancy more frequently than other women in the population.

In the current study, Jeanette Falck Winther, M.D., of the Danish Cancer Society in Copenhagen, and colleagues compared the proportion of pregnancies that ended in an induced abortion in 1,688 adult survivors of pediatric cancer who were included in the Danish Cancer Registry, in 2,737 of their sisters who did not have pediatric cancer, and in 16,700 women randomly selected from the Danish Central Population Register.

Cancer survivors chose to have an induced abortion in 19.7% of their pregnancies, which was similar to the proportion of pregnancies terminated by their sisters (18.9%) and by women in the general population (19.7%).

Although Danish records do not track a woman's reason for a first-trimester abortion, the reason for a second trimester abortion is recorded. "Survivors were not more likely than sisters and population control subjects to elect a second-trimester abortion because of physical and mental conditions or fetal abnormalities," the authors conclude.

Contact: Jeanette Falck Winther, M.D., jeanette@cancer.dk, +45 35257670


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. U.S. Census Bureau Daily Feature for April 28
2. Donate Life California to Hold Press Conference Commemorating Donation Heroes Tuesday, April 28, 10:00 a.m., State Capitol
3. Donate Life California to Hold Press Conference on Organ Donation Education, April 28, 1:30 p.m., on State Capitol West Steps
4. Kaiser Permanente Continues to Spread Health With New Ads Debuting in April
5. Omnicell to Release First Quarter 2009 Earnings Results on April 30
6. Largest Organ and Tissue Donation Event in U.S.: Seventh Annual Donate Life Run/Walk & Family Festival, Sat., April 25 at Cal State Fullerton
7. Seniors Invited to Learn About Fraud Prevention at SCAN Connections Resource Center on April 28
8. Light of Hope: Help for Children with Autism Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders
9. Palomar Medical Technologies to Host First Quarter 2009 Financial Results Conference Call and Webcast on April 30, 2009
10. Turn the Corner Foundation Rings in Lyme Disease Awareness Month Early at NYSE on April 23, 2009
11. YWCA USA to Observe World YWCA Day - April 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies ... quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known as ... kidneys, liver and pancreas. If not properly addressed, visceral fat can lead to ... Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral fat. ...
(Date:5/2/2016)... (PRWEB) , ... May 02, ... ... researchers report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants ... mitigate these risks, Novus Medical Detox Center —a leading Florida-based drug ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Pregnancy Awareness Month ... trying to conceive. , “If you are ready to have a baby, ... “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy Organizer, written ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... and urgent care facilities designed to automate and improve the rapid diagnosis, triage ... it is demonstrating their platform, application, and mobile experience for the first time ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology: